Asthma
Pipeline by Development Stage
Drug Modality Breakdown
Asthma is a $1.5B market in mature consolidation, dominated by legacy inhalers and rapidly growing biologic therapies.
Key Trends
- Shift from corticosteroid monotherapy to biologic IL-5 and TSLP antagonists for moderate-to-severe asthma
- Patent cliff risk: $395M FLOVENT HFA loses exclusivity in 2026, reshaping GSK's market position
- Robust clinical pipeline with 1,736 trials across all phases, signaling continued innovation in precision asthma phenotyping
Career Verdict
Strong opportunity for specialists in biologics development and commercial launch strategy, but avoid pure small-molecule inhalers due to commoditization and upcoming generic erosion.
AI-generated market analysis based on FDA, CMS, ClinicalTrials.gov, and hiring data
Market Leaders
| # | Product | Company | Revenue | Share | Stage | Trend | LOE |
|---|---|---|---|---|---|---|---|
| 1 | FLOVENT HFA (fluticasone propionate) | GSK | $395M | 26% | LOE_APPROACHING | Declining | 0.3yr |
| 2 | NUCALA (mepolizumab) | GSK | $261M | 17% | PEAK | Stable | |
| 3 | XOLAIR (omalizumab) | Roche | $254M | 17% | LOE_APPROACHING | Stable | |
| 4 | VENTOLIN HFA (albuterol sulfate) | GSK | $193M | 13% | LOE_APPROACHING | Declining | |
| 5 | TEZSPIRE (tezepelumab-ekko) | AstraZeneca | $88M | 6% | PEAK | Growing |
Drug Class Breakdown
declining due to patent cliffs and generics
growing, established as standard for eosinophilic asthma
stable, mature indication
declining, generic commodity
rapidly growing, newest mechanism with broad phenotype coverage
Career Outlook
StableAsthma remains a mature, stable market with ~$1.5B spend, but structural shift from small-molecule inhalers to biologics (IL-5, TSLP, IgE antagonists) creates bifurcated career paths: declining prospects in generic/commodity inhaler roles vs. strong growth in biologic launch, real-world evidence, and precision phenotyping. Patent cliffs for FLOVENT HFA (2026) and XOLAIR (no date disclosed but competitive pressure rising) will drive consolidation and cost discipline among legacy players like GSK and Roche.
Breaking In
Target AstraZeneca, GSK, or Roche for entry-level Commercial or Clinical Ops roles; emphasize respiratory disease knowledge and willingness to specialize in biologics rather than commodity inhalers.
For Experienced Professionals
Leverage legacy ICS/SABA experience to pivot into biologic lifecycle management or real-world evidence roles; avoid pure franchise management of FLOVENT/VENTOLIN post-2026 LOE without clear transition plan.
In-Demand Skills
Best For
Hiring Landscape
Asthma-focused roles total 7,970 jobs across 15 companies, with Commercial roles dominating (1,447 positions) and Medical Affairs emerging as growth area (264 roles). GSK leads in asthma headcount (745 jobs), followed by AstraZeneca (1,373 jobs across broader respiratory) and Roche (1,034 jobs); however, broader pharma hiring data shows AstraZeneca, Takeda, and J&J expanding aggressively, suggesting market consolidation around biologic platforms.
By Department
Commercial and Medical Affairs roles offer best stability and compensation; however, R&D and Clinical Operations roles signal innovation activity and long-term career depth in biologics specialization.
On Market (25)
Approved therapies currently available
Competitive Landscape
129 companies ranked by most advanced pipeline stage
+99 more companies
Trial Timeline
Clinical trial activity over time
Showing 15 of 50 trials with date data
Clinical Trials (50)
Total enrollment: 13,539 patients across 50 trials
Individualizing Treatment for Asthma in Primary Care (Full Study)
Effect of Dupilumab on the Muscle Function of the Esophagus (food Pipe) in Participants with Eosinophilic Esophagitis (EoE)
Combination Short-Acting BroNchodilator and Inhaled Corticosteroid Rescue Therapy on Health Outcomes in Routine Care
REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study
Bioequivalence Study of Methacholine for Inhalation (pharmacodynamics)
Individualizing Treatment for Asthma in Primary Care
Symptoms Control and adhErenCe Assessment During Treatment With MepolizUmab New pREfilled Devices
BURAN: Benralizumab on Airway Dynamics in Severe Eosinophilic Asthma Using Functional Respiratory Imaging
Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP
CARE FOR ALL：an Evaluation of an Asthma QIP
Viral Infection in Asthma (VIA) Study
Step-up to Medium Strength Triple Therapy vs High Strength ICS/LABA in Adult Asthmatics Uncontrolled on Medium Strength ICS/LABA
Effects of Interleukin (IL)- 4R-alpha Inhibition on Respiratory Microbiome and Immunologic Correlates in Severe Asthma
FAsenra Safety Trial in India
Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing
Predictive Signature of Benralizumab Response
Investigating Dupilumab's Effect in Asthma by Genotype
Teva Asthma Predictive Analytics Study
Efficacy and Safety Study of Mepolizumab 100 Milligram (mg) Subcutaneous (SC) in Indian Participants Aged Greater Than or Equal to (>=) 18 Years With Severe Eosinophilic Asthma
Effect of Electronic Monitoring and Feedback on Adherence to Easyhaler Controller Medication in Patients With Asthma
A Comparison of Critical Errors, Overall Errors, Training/Teaching Time, and Preference Attributes of the ELLIPTA Versus BREEZHALER Dry Powder Inhalers (DPIs) in Adult Participants With Asthma
A 24-Week Treatment Study to Compare Standard of Care Versus the eMDPI DS in Participants 13 Years or Older With Asthma
A 12-Week Treatment Study to Evaluate the Effectiveness of Albuterol Multidose Dry Powder Inhaler With Integrated Electronic Module Digital System (eMDPI DS) in Participants13 Years or Older With Asthma
A Study to Assess the Reduction of Daily Maintenance ICS/LABA Treatment Towards Anti-Inflammatory Reliever Treatment in Patients With Severe Eosinophilic Asthma Treated With Benralizumab
The Effect of Dupilumab on Lung Inflammation and Related Changes in Airway Volumes Detectable by Functional Respiratory Imaging in Patients With Moderate-severe Asthma
The Effects of Dupilumab on Allergic Contact Dermatitis
Benralizumab Exacerbation Study
Clinical Equivalence of Budesonide HFA MDI Versus Budesonide Turbuhaler in Mild to Moderate Chinese Asthma Patients
Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".
The Impact of Dupilumab on Quality of Life in Moderate to Severe Atopic Dermatitis Patients
The Efficacy of Fluticasone Furoate/Vilanterol Versus (vs) Fluticasone Furoate on Asthma
A Clinical Study to Evaluate the Effect of the Connected Inhaler System (CIS) on Adherence to Maintenance Therapy in Poorly Controlled Asthmatic Subjects
An Imaging Study Using PET/CT to Characterize the Effect of Intravenous Reslizumab on Airway Inflammation
C1-inhibitor in Allergic ASThma Patients
Asthma Control Test Guided Treatment in Chinese Subjects
Phase IV Study in Asthma Subjects for Dry Powder Inhaler (DPI) Versus (vs) Metered Dose Inhaler (MDI) Correct Use
Omalizumab to Mepolizumab Switch Study in Severe Eosinophilic Asthma Patients
Longitudinal Cohort Study in Participants With Severe Asthma to Assess Biomarkers
A Non-inferiority Study to Evaluate Efficacy, Safety and Tolerability of NEUMOTEROL® 400 and SYMBICORT® Forte in Adults With Asthma
To Study Device Attributes by Investigating Errors Made in Use, Ease of Use and Preference Among Different Inhalers in Subjects With Asthma
Positive Expiratory Pressure for the Treatment of Acute Asthma in Children
Efficacy and Safety of Fluticasone Propionate(FP)/ Salmeterol Xinafoate (SLM) Hydro Fluoro Alkane (HFA) Metered Dose Inhaler (MDI) in Pediatric Patients With Bronchial Asthma
Improving Asthma Control in the Real World: A Systematic Approach to Improving Dulera Adherence
Targeted Small Airways Therapy in Persistent Asthma
Dose-Response of Salmeterol in Children
Effects of Particle Size in Small Airways Dysfunction
Effects of QVAR in Smokers With Asthma
Symbicort in Airway Predominant Chronic Obstructive Pulmonary Disease (COPD)
Long-acting Beta Agonist Step Down Study
Effects of Leukotriene Modulator Montelukast on Cough Variant Asthma
Related Jobs in Respiratory
Brand Lead Eosinophilic Diseases (EGPA/HES) (m/f/d), befristet bis November 2027
Vendor Alliance Lead Associate Director (Cardiac Safety and Respiratory Diagnostics)
Bölge Satış Müdürü, PAH
Sr. Pharmaceutical Info Specialist, PAH
Sr. Pharmaceutical Info Specialist, PAH
Sr. Specialist, Engineering (Onsite)
Phase Legend
Key Insights
Related Indications
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.